Novavax, Inc. (Nasdaq: NVAX), a US-based biotechnology company, announced on Friday that it has received expanded emergency use authorisation (EUA) from the Taiwan Food and Drug Administration (TFDA) for its Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 to 17.
The approval is based on data from the ongoing paediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents aged 12 to 17 years across 75 sites in the United States to assess the safety and effectiveness of the product.
Preliminary safety data from the paediatric expansion indicated the vaccine to be generally well-tolerated.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review